Methods to express recombinant proteins from lentiviral vectors

Details Methods to express recombinant proteins from lentiviral vectors Methods to express recombinant proteins from lentiviral vectors

2006-07-18

2009-12-15

Nickol, Gary B (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S199100, C424S184100, C424S202100, C424S130100, C435S320100, C435S235100, C435S239000, C530S387100

Reexamination Certificate

active

07632509

ABSTRACT:
Lentivector constructs for expression of recombinant proteins, polypeptides or fragments thereof and methods of making the same are described. The lentivectors typically have a self-processing cleavage sequence between a first and second protein or polypeptide coding sequence allowing for expression of a functional protein or polypeptide under operative control of a single promoter and may further include an additional proteolytic cleavage sequence which provides a means to remove the self-processing cleavage sequence from the expressed protein or polypeptide. The vector constructs find utility in methods relating to enhanced production of biologically active proteins, such as immunoglobulins or fragments thereof in vitro and in vivo.

REFERENCES:
patent: 5310903 (1994-05-01), Goulet et al.
patent: 5362718 (1994-11-01), Skotnicki et al.
patent: 5436146 (1995-07-01), Shenk et al.
patent: 5525610 (1996-06-01), Caufield et al.
patent: 5573500 (1996-11-01), Katsunuma
patent: 5686279 (1997-11-01), Finer et al.
patent: 5846767 (1998-12-01), Halpin et al.
patent: 6015709 (2000-01-01), Natesan
patent: 6040183 (2000-03-01), Ferrari et al.
patent: 6093570 (2000-07-01), Ferrari et al.
patent: 6117680 (2000-09-01), Natesan et al.
patent: 6133456 (2000-10-01), Holt et al.
patent: 6150527 (2000-11-01), Holt et al.
patent: 6171586 (2001-01-01), Lam et al.
patent: 6187757 (2001-02-01), Clackson et al.
patent: 6261567 (2001-07-01), Hart et al.
patent: 6306649 (2001-10-01), Gilman et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6479653 (2002-11-01), Natesan et al.
patent: 6506379 (2003-01-01), Clackson et al.
patent: 6548286 (2003-04-01), Samulski et al.
patent: 6602503 (2003-08-01), Lobb et al.
patent: 6623940 (2003-09-01), Ledbetter et al.
patent: 6632800 (2003-10-01), Russell et al.
patent: 6649595 (2003-11-01), Clackson et al.
patent: 6692736 (2004-02-01), Yu et al.
patent: 6933362 (2005-08-01), Belfort
patent: 7001596 (2006-02-01), Johnson et al.
patent: 7485291 (2009-02-01), Fang et al.
patent: 7498024 (2009-03-01), Fang et al.
patent: 2002/0168339 (2002-11-01), Piechaczyk et al.
patent: 2003/0068307 (2003-04-01), Yu
patent: 2003/0099932 (2003-05-01), Lorens
patent: 2004/0086485 (2004-05-01), Cordova
patent: 2004/0131591 (2004-07-01), Kingsman
patent: 2004/0209830 (2004-10-01), Russell
patent: 2004/0235011 (2004-11-01), Cooper
patent: 2004/0235173 (2004-11-01), Bleck et al.
patent: 2004/0235955 (2004-12-01), Fang et al.
patent: 2004/0265955 (2004-12-01), Fang et al.
patent: 2005/0003482 (2005-01-01), Fang et al.
patent: 2005/0042721 (2005-02-01), Fang et al.
patent: 2005/0060762 (2005-03-01), Bleck
patent: 2005/0095705 (2005-05-01), Kadan et al.
patent: 2006/0034805 (2006-02-01), Fang et al.
patent: 2006/0228336 (2006-10-01), Ko
patent: 2006/0292682 (2006-12-01), Hawkins et al.
patent: 2007/0059820 (2007-03-01), Fang et al.
patent: 2007/0065912 (2007-03-01), Carson et al.
patent: 2007/0275915 (2007-11-01), Hallenbeck et al.
patent: 2007/0292922 (2007-12-01), Fang et al.
patent: 2008/0280356 (2008-11-01), Fang et al.
patent: WO 92/08793 (1992-05-01), None
patent: WO 97/28272 (1997-08-01), None
patent: WO 2004/113493 (2004-12-01), None
patent: WO 2007/126805 (2007-11-01), None
Lamikama et al., In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies, 2005, Gene Therapy, vol. 12, pp. 988-998.
O'Rourke et al., Comparison of Gene Transfer Efficiencies and Gene Expression Levels Achieved with Equine Infectious Anemia Virus- and Human Immunodeficiency Virus Type 1-Derived Lentivirus Vectors, 2002, Journal of Virology, vol. 76, No. 3, pp. 1510-1515.
Chazenbalk et al., Evidence for negative cooperativity among human thyrotropin receptors overexpressed in mammalian cells, 1996, Endocrinology, vol. 137, pages abstract.
Collet et al., A binary plasmid system for shuffling combinatorial antibody libraries, 1992, PNAS, vol. 89, pp. 10026-10030.
Loiler et al., Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver, 2003, Gene Therapy, vol. 10, pp. 1551-1558.
Fang et al., Stable antibody expression at therapeutic levels using the 2A peptide, 2005, Nature Biotechnology, vol. 23, No. 5, pp. 584-590.
Szymczak et al., Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector, 2004, Nature Biotechnology, vol. 22, No. 5, pp. 589-594.
Altschul, Stephen F., et al., “Basic Local Alignment Search Tool,”Journal of Molecular Biology(1990), vol. 215, pp. 403-410, Academic Press Limited, USA.
Bosselman, Robert A., et al., “Replication-Defective Chimeric Helper Proviruses and Factors Affecting Generation of Competent Virus: Expression of Moloney Murine Leukemia Virus Structural Genes via the Metallothionein Promoter,”Mollecular and Cellular Biology(May 1987), vol. 7, No. 5, pp. 1797-1806, American Society for Microbiology, USA.
Capecchi, Mario R., “High Efficiency Transformation by Direct Microinjection of DNA into Cultured Mammalian Cells,”Cell(Nov. 1980 (Part 2)), vol. 22, pp. 479-488, MIT, USA.
Chaplin, Paul J., et al., “Production of Interleukin-12 as a Self-Processing 2A Polypeptide,”Journal of Interferon and Cytokine Research(1999), vol. 19, pp. 234-241.
Danos, Olivier and Mulligan, Richard C., “Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges,”Proc. Natl. Acad. Sci. USA(Sep. 1988), vol. 85, pp. 6460-6464.
De Felipe, P., et al., “Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy,”Gene Therapy(1999), vol. 6, pp. 198-208, Stockton Press, UK.
De Felipe, Pablo and Izquierdo, Marta, “Tricistronic and Tetracistronic Retroviral Vectors for Gene Transfer,”Human Gene Therapy(Sep. 1, 2000), vol. 11, pp. 1921-1931.
Donnelly, Michelle L. L., et al., “The cleavage activities of aphthovirus and cardiovirus 2A proteins,”Journal of General Virology(1997), vol. 78, pp. 13-21, UK.
Donnelly, Michelle L. L., et al., “Analysis of the aphthovirus 2A/2B polyprotein ‘cleavage’ mechanism indicates not a proteolytic reaction, but a novel translation effect: a putative ribosomal ‘skip’,”Journal of General Virology(2001), vol. 82, pp. 1013-1025, UK.
Donnelly, Michelle L. L., et al., “The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences,”Journal of General Virology(2001), vol. 82, pp. 1027-1041, UK.
Duke, Gregory M., et al., “Sequence and Structural Elements That Contribute to Efficient Encephalomyocarditis Virus RNA Translation, ”Journal of Virology(Mar. 1992), vol. 66, No. 3, pp. 1602-1609.
Dull, Tom, et al., “A Third-Generation Lentivirus Vector with a Conditional Packaging System,”Journal of Virology(Nov. 1998), vol. 72, No. 11, pp. 8463-8471.
Felgner, Philip L., et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure,”Proc. Natl. Acad. Sci USA(Nov. 1987), vol. 84, pp. 7413-7417.
Furler, S., et al., “Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neurons,”Gene Therapy(2001), vol. 8, pp. 864-873, Nature Publishing Group, USA.
Green, I.L., et al., “Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs,”Nature Genetics(May 1994), vol. 7, pp. 13-21, Nature Publishing Group, USA.
Guo, Zs, et al., “Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer,”Gene Therapy(1996), vol. 3, pp. 802-810, Stockton Press,UK.
Halpin, Claire, et al., “Self-processing 2A-polyproteins—a system for co-ordinate express of multiple proteins in transgenic plants,

Affiliated with

Also associated with

Rating

Methods to express recombinant proteins from lentiviral vectors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods to express recombinant proteins from lentiviral vectors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to express recombinant proteins from lentiviral vectors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4112280